Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS). (April 2017) - Stein, E.M.; Fathi, A.T.; DiNardo, C.D.; Pollyea, D.A.; Swords, R.T.; Roboz, G.J.; Collins, R.; Sekeres, M.A.; Stone, R.M.; Attar, E.C.; Tosolini, A.; Xu, Q.; et al.